PERceptions of Diltiazem Versus ADEnosine for Treatment of Supraventricular Tachycardia in the Emergency Department

Active, not recruiting

• Conditions: Supraventricular Tachycardia (SVT)
• Interventions: Drug: IV adenosine; Drug: IV diltiazem

• Registration Number: NCT07086560
• Lead Sponsor: University of Iowa

Brief Summary

Supraventricular tachycardia (SVT) is a dysrhythmia characterized rapid heart rate, typically with rapid onset. SVT accounts for over 50,000 emergency department visits per year. Of patients with regular, narrow-complex SVT, the mainstay of therapy includes adenosine and diltiazem. Adenosine is recommend by American and European guidelines as first-line therapy, however adenosine carries unique side effects that are potentially distressing to patients, including: "feeling of impending death or doom", flushing, anxiety, shortness of breath, and chest discomfort. Diltiazem does not carry this side effect profile, but has typically been reserved as second-line treatment due to side effects of low blood pressure associated with this class of medications. Diltiazem and adenosine have not been well studied head-to-head to compare safety and efficacy of their treatment for SVT. The purpose of this study is to evaluate safety and efficacy of adenosine and diltiazem for SVT in the ED (as completed through chart review of specific patient-level outcomes) and capture patient and clinician perspectives of medication satisfaction (through administration of questionnaires).

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-04
• Study Start: 2025-04-04
• Study First Submitted: 2025-04-04
• Study First Submitted QC: 2025-07-22
• Last Update Submitted: 2025-07-22
• Study First Posted: 2025-07-25
• Last Update Posted: 2025-07-25
• Primary Completion: 2026-06
• Study Completion: 2026-12-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. ED encounter for acute SVT
2. Age >/= 18 years
3. Receipt of IV adenosine and/or IV diltiazem for SVT in the ED or prehospital setting

Exclusion Criteria

1. Neurologic status precluding survey participation due to medical instability
2. Pregnant
3. Incarcerated
4. Non-English speaking

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Adenosine	IV adenosine	-
Diltiazem	IV diltiazem	-

Primary Outcome Measures

Name	Time	Method
Patient satisfaction with SVT treatment	Primary outcome will be assessed during ED visit	Patient satisfaction with treatment will be assessed using a Likert scale questionnaire of 1-5. Participants will indicate their satisfaction with treatment by indicating a score of 1-5, 1 being "not at all satisfied" and 5 being "extremely satisfied".

Trial Locations

Locations (1)

University of Iowa Health Care; 🇺🇸 Iowa City, Iowa, United States